PHILADELPHIA, PA / ACCESSWIRE / October 4, 2022 / Berger Montague is currently investigating potential violations of the federal securities laws on behalf of shareholders of I-Mab (NASDAQ:IMAB).
I-Mab is a clinical stage biopharmaceutical company that discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. On January 17, 2020, I-Mab conducted its initial public offering (“IPO”), selling more than 7 million American depositary shares (“ADSs”) priced at $14.00 per ADS.
On August 16, 2022, I-Mab disclosed in a filing with the SEC that its collaboration partner “AbbVie will discontinue the global Phase 1b study of [I-Mab’s] lemzoparlimab combination therapy with azacitidine (‘AZA’) and venetoclax, in patients with myelodysplastic syndrome (‘MDS’) and acute myelocytic leukemia (‘AML’).”
Following this news, I-Mab’s ADS price fell $1.14 per ADS, or 14.3%, to close at $6.83 per ADS on August 17, 2022, which is a decline of 51.21% from the IPO price.
If you are an I-Mab investor and would like to learn more about our investigation, please contact Berger Montague PC: James Maro at jmaro@bm.net or (215) 875-3093, or Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015; or please visit the following link to fill out our online form https://investigations.bergermontague.com/i-mab/
Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
CONTACT:
James Maro, Senior Counsel
Berger Montague
(215) 875-3093
jmaro@bm.net
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net
SOURCE: Berger Montague
View source version on accesswire.com:
https://www.accesswire.com/718797/INVESTIGATION-ALERT-Berger-Montague-PC-is-Investigating-Securities-Fraud-Claims-on-Behalf-of-I-Mab-NASDAQ-IMAB-Investors
